Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) (PAR-25-048)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America (R01 - Clinical Trials Not Allowed) (PAR-25-377)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Notice of Special Interest (NOSI): Selective Cell and Network Vulnerability in Aging and Alzheimers Disease (NOT-AG-24-033)

Sponsor: National Institute on Aging

Award: Submit applications for this initiative using one of the following notices of funding opportunities (NOFOs) or any reissues of these announcements through the expiration date of this notice: PAR-25-331 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional); PAR-25-332 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

Due Date: This notice applies to due dates on or after March 11, 2025 and subsequent receipt dates through November 17, 2027.

Notice of Special Interest (NOSI): Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) and Cognitive Resilience (NOT-AG-24-042)

Sponsor: National Institute on Aging

Award: Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcements through the expiration date of this notice: PAR-25-331 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional); PAR-25-332 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

Due Date: This notice applies to due dates on or after March 11, 2025 and subsequent receipt dates through November 17, 2027.

Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed) (PA-25-150)

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH)

Award: Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.

Due Date: Multiple due dates; see announcement.

Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) (PA-25-169)

Sponsor: National Institutes of Health

Award: Application budgets may not exceed $400,000 direct costs over a maximum three-year funding period. No more than $200,000 direct costs may be requested in any single year.

Due Date: Multiple due dates; see announcement.

Notice of Special Interest (NOSI): Novel Approaches to Characterizing and Diagnosing Alzheimer's Disease and Related Dementias (NOT-AG-24-030)

Sponsor: National Institute on Aging

Award: Submit applications for this initiative using one of the following notices of funding opportunities (NOFOs) or any reissues of these announcements through the expiration date of this notice: PAR-25-331 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional); PAR-25-332 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

Due Date: This notice applies to due dates on or after March 11, 2025 and subsequent receipt dates through November 17, 2027 .

Accelerating and Scaling Biological Sciences with AI

Sponsor: The Chan Zuckerberg Initiative (CZI)

Award: This grant is for an allocation of CZI’s GPU resource (minimum request of 96 GPU). This is an in-kind award; there are no cash funds, financial contributions, or fees of any kind associated with the award.

Due Date: Submitted applications will be downloaded for consideration at 1 p.m. Pacific Time on the third Wednesday of every month (through June 18, 2025) until cluster access is allocated. CZI reserves the right to stop accepting applications at any time.

Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for AD and ADRD (R01 Clinical Trial Not Allowed) (PAR-25-374)

Sponsor: National Institute on Aging

Due Date: Multiple due dates; see announcement.

Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35) (PA-25-280)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional) (RFA-NR-25-003)

Sponsor: National Institutes of Health

Due Date: Letter of Intent due January 29, 2025. Application due February 28, 2025.

Notice of Special Interest (NOSI): Human Cell Biology of Alzheimer's Disease Genetic Variants (NOT-AG-24-039)

Sponsor: National Institute on Aging

Award: Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcements through the expiration date of this notice: PAR-25-331 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional); PAR-25-332 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional).

Due Date: This notice applies to due dates on or after March 11, 2025 and subsequent receipt dates through November 17, 2027.

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) (PAR-25-331)

Sponsor: National Institute on Aging

Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 in direct costs may be requested in any single year.

Due Date: Multiple due dates; see announcement.

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) (PAR-25-332)

Sponsor: National Institute on Aging, National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional) (PAR-25-327)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.